What did the FDA warn Novo Nordisk about?

The FDA sent Novo Nordisk a warning letter on March 5, 2026, because the company was not properly reporting side effects for its GLP-1 medications. That includes semaglutide, the active ingredient in Ozempic and Wegovy. The FDA found that deaths and other serious side effects were not reported within the required 15-day window, and that the company’s internal process was filtering out reports that should have gone through (FDA Warning Letter).

Does this mean Ozempic or Wegovy is unsafe?

The FDA did not say these medications are unsafe. The issue is that Novo Nordisk was not reporting certain side effects the way it is supposed to. That means the FDA may not have had the full picture when reviewing safety for these drugs. The FDA depends on companies sending complete information so it can spot potential problems early (FDA Warning Letter).

Did Novo Nordisk fix the problems?

The company says it has been making changes since the FDA inspected its offices, including updating its procedures and planning to handle safety reports with its own staff instead of outside call centers (PharmExec). The FDA said the company’s response so far has not been detailed enough and gave Novo Nordisk 15 days to come back with a stronger plan (FDA Warning Letter).

Were the reported deaths caused by semaglutide?

The FDA did not say semaglutide caused the deaths. The problem is that these cases were never properly reported or investigated. Without that data reaching the FDA, nobody can say one way or the other (FDA Warning Letter).

Where can I learn more about GLP-1 side effects?

GLP Winner has a full, sourced article on the most common GLP-1 side effects and when they happen. You can also read about the FDA review that found no link between GLP-1 medications and suicide risk, or explore providers and pricing with the GLP Winner comparison tool.

FDA Warns Novo Nordisk on GLP-1 Death Reports | GLP Winner | GLP Winner

On March 5, 2026, the FDA sent Novo Nordisk a warning letter after finding the company did not properly report deaths and serious side effects connected to its GLP-1 medications, including Ozempic and Wegovy (FDA Warning Letter).

Who This Helps

This is for you if you take a GLP-1 medication, or if you are thinking about starting one. It covers what the FDA found, what Novo Nordisk did wrong, and why it matters for anyone who depends on these medications.

New to the term GLP-1? GLP Winner has a simple guide that explains GLP-1, GLP-2, and GIP in plain language.

What Happened

The FDA sent Novo Nordisk a warning letter on March 5, 2026 (FDA Warning Letter). The letter says the company broke the rules on how it tracks and reports side effects for its medications.

Here is how this works. When someone takes a medication and something goes wrong, the drug company is required by law to report it to the FDA within 15 days (FDA Warning Letter). The FDA says Novo Nordisk was not doing that.

The FDA looked into this during an inspection of Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey, between January 13 and February 7, 2025.

The letter specifically named semaglutide, the active ingredient in Ozempic and Wegovy. Both are FDA-approved GLP-1 receptor agonists, which is the medical term for medications that activate a receptor in your body that helps with blood sugar and appetite. The letter also named liraglutide, the active ingredient in Saxenda, another GLP-1 medication (FDA Warning Letter).

Sabina from GLP Winner broke this story down on video. You can watch her full take on TikTok or YouTube.

What the FDA Found

The FDA identified three separate problems with how Novo Nordisk was handling safety reports.

1. Throwing out side effect reports based on company judgment

Novo Nordisk’s own internal rules let staff toss out side effect reports if someone at the company decided the problem was unrelated to the drug (FDA Warning Letter). But the FDA’s rules are clear: companies have to report every side effect they hear about, even if they think the drug did not cause it. That call belongs to the FDA, not the company selling the medication.

2. Saying patient details were missing when they were actually there

The company and its call-center contractors were closing out cases because they said they could not identify the patient (FDA Warning Letter). But when FDA investigators looked at the original paperwork during the inspection, the patient details were right there. In one case, a patient's death went unreported because a staff member missed information that was sitting in the file.

3. Letting safety reviews sit untouched for weeks

Some cases that needed a medical review just sat in a queue, untouched, well past the company’s own deadlines (FDA Warning Letter). One example: a report about a patient having suicidal thoughts while taking semaglutide came in during December 2024. Nobody reviewed it until February 2025, and only after FDA inspectors flagged it during the inspection.

On top of all that, the FDA found that Novo Nordisk required its staff to get permission from whoever reported a side effect before they could follow up on it (FDA Warning Letter). There is no rule that requires that. And because of it, at least one patient's death was never looked into and never reported.

If you want a broader look at what side effects come with GLP-1 medications, GLP Winner has a full breakdown: the most common GLP-1 side effects and when they happen.

What this means for you: Novo Nordisk’s internal process was filtering out safety reports before they ever reached the FDA. That means the people making decisions about these drugs may not have been seeing the full picture.

The Specific Cases in the Letter

The warning letter names three patient deaths involving semaglutide that were never properly looked into or reported to the FDA (FDA Warning Letter). One of those cases involved a suicide (NBC News).

There was also a patient who experienced suicidal thoughts while taking semaglutide. Novo Nordisk received that report in December 2024 but did not review it for months (FDA Warning Letter).

The letter also mentions a separate case where a patient had a disabling stroke while taking liraglutide, another GLP-1 medication. That one was not reported either.

To be clear: the FDA did not say these medications caused these events. The problem is that they were never properly reported. Without that information reaching the FDA, the agency had no way to look into whether a connection exists (FDA Warning Letter).

On the topic of suicide specifically, the FDA completed a separate review in 2025 and found no connection between GLP-1 medications and suicide risk. GLP Winner covered that here: FDA Review Finds No Link Between GLP-1 Medications and Suicide Risk.

What this means for you: An unreported event does not mean the medication caused it. It means the FDA never got the chance to find out.

How Novo Nordisk Responded

Novo Nordisk said it has been working on fixes since the inspection (PharmExec). Here is what the company says it is doing:

Updating its rules so staff can no longer dismiss reports based on their own judgment about whether the drug caused the problem
Going back through old cases to check for anything that should have been reported
Reviewing patient safety cases every day instead of letting them pile up
Moving safety case handling away from outside call centers and bringing it in-house with trained healthcare staff

The FDA was not convinced. The agency called Novo Nordisk’s response “inadequate” because it did not include enough detail about how the company would prevent this from happening again (FDA Warning Letter). Novo Nordisk has 15 days to come back with a stronger plan, or it could face further action from the FDA.

This is also not the first time the FDA brought this up. The agency had flagged similar problems about a year earlier, and the warning letter makes clear that nothing changed (FDA Warning Letter).

The FDA used the word “systemic” to describe these problems and said the issues could stretch across Novo Nordisk’s full lineup of medications, not just semaglutide and liraglutide.

For more on what Novo Nordisk has been up to recently, GLP Winner covered the Novo Nordisk and Hims deal and what it means for GLP-1 pricing and access.

Why This Matters If You Take a GLP-1

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are some of the most prescribed medications in the country. Millions of people take them. You deserve to know that the safety information behind those medications is complete.

When a drug company does not report side effects on time, it leaves a gap. Your doctor makes choices based on what the FDA knows. You weigh the risks based on the same information. If the FDA is working with an incomplete picture, that affects everyone.

This also has a bigger backdrop worth paying attention to. Novo Nordisk has been a vocal player in conversations about the safety of compounded GLP-1 products. GLP Winner has been tracking those developments in articles like New Compounding Laws Could Affect GLP-1 Access in 2026 and the Indiana, Florida, and Federal GLP-1 Compounding Law Update.

GLP Winner exists to help you compare GLP-1 providers, understand what things cost, and get clear information you can trust. You can explore options through the GLP Winner comparison tool. Transparency from manufacturers is a big part of what makes that possible.

Curious about GLP-1 pricing? See If Ozempic Costs $3 to Make, Why Does It Cost $900?.

What This Means in 2026

This warning letter lands in the middle of a busy year for GLP-1 regulation. The FDA has been updating its positions on compounding, supply chains, and how companies track safety throughout 2025 and into 2026. GLP Winner follows these changes closely through the Insights blog.

GLP-1 prescriptions keep growing. Insurance coverage is still inconsistent. And the rules around both branded and compounded GLP-1 products are shifting regularly.

A warning letter like this one signals that the FDA is watching how big drug companies handle their safety responsibilities after a medication reaches the market. For anyone taking one of these medications, it is a good reminder to stay informed through sources you trust.

Final Takeaway

The FDA’s warning letter to Novo Nordisk raises real questions about how safety information for some of the most widely used GLP-1 medications has been handled.

These are medications that millions of people take every day. Reporting side effects on time is a basic part of how the system is supposed to work. The FDA found that was not happening.

That does not mean these medications are unsafe. It means that for a period of time, the FDA, your doctor, and you may not have had the full picture.

The best thing you can do is stay informed. Look at the sources. Talk to your doctor. Keep paying attention to what the FDA says.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

FDA Sends Warning Letter to Novo Nordisk Over Unreported GLP-1 Deaths and Side Effects

Sources

Keep Reading

What Are the Most Common GLP-1 Side Effects and When Do They Happen?

FDA Review Finds No Link Between GLP-1 Medications and Suicide Risk

The Novo Nordisk and Hims Deal: What It Means for GLP-1 Pricing and Access

New Compounding Laws Could Affect GLP-1 Access in 2026

Categories

Curated by